Business Wire

Adtran’s Oscilloquartz optical cesium clock outperforms in tests at leading European metrology institute

5.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Adtran today announced that one of the world’s leading metrology institutes has conducted a three-month-long evaluation of its OSA 3300-HP high-performance optical cesium atomic clock. Based in Central Europe, the national laboratory tested Adtran’s industry-first solution to establish its suitability for scientific measurement and calibration applications that require precise synchronization. The OSA 3300-HP succeeded in delivering the strict timing accuracy and long-term stability needed for metrology use cases with results far exceeding product specifications. The findings underline the value of Adtran’s Oscilloquartz optical cesium technology for a broad spectrum of industries, from astronomical research to defense operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905097567/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s OSA 3300-HP has set new benchmarks for timing accuracy and long-term stability. (Photo: Business Wire)

“We’re pleased to see this validation for our OSA 3300-HP. As the market’s first commercial high-performance optical cesium atomic clock, it offers levels of performance that far exceed best-in-class magnetic cesium devices. Its unique capabilities have the potential to enhance the work of scientists and engineers in a diverse range of metrology, science, research, time scale and ground station fields, including space exploration,” said Gil Biran, GM of Oscilloquartz, Adtran. “Now that it’s achieved these successful results in some of the industry’s most thorough tests, science and research institutions across the world will be able to harness our device to bring new levels of accuracy to their work.”

Adtran’s OSA 3300-HP represents a major achievement in network synchronization. Building on Oscilloquartz’s 74-year history and the expertise of its team, the device provides a precise and ultra-stable frequency source for the most demanding and critical applications. It enables highly accurate synchronization over an extended 10-year lifetime thanks to its advanced optical cesium technology, which pumps atoms to the desired energy states more efficiently than legacy magnetic-based solutions. The OSA 3300-HP’s robust and compact design makes it suitable for multiple applications, even in ground space-constrained environments. It’s also fully compliant with the latest RoHS standards and strict EU demands.

“Assessments by this leading scientific evaluation center are recognized as among the most stringent evaluations in the world of metrology. By meeting and surpassing these rigorous standards, our OSA 3300-HP has proven its value for metrology, time-keeping institutes and scientific research. It will be the foundation for future innovation in sectors from satellite navigation to nanoscale technology,” commented Jörg Urban, AVP of EMEA business development at Oscilloquartz, Adtran. “Our optical pumping timing solutions have set a new benchmark for precision and availability. As well as having a transformative impact on metrology advancement, our technology provides the vital resilience required for PNT assurance in critical infrastructure. What’s more, it empowers communication service providers to harness robust and accurate GNSS backup to deliver valuable timing offerings with differentiated service level agreements.”

Further details including official results from the OSA 3300-HP evaluation are now available on request.

A brief summary of the findings can also be found in these slides.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com

For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye